Insights

Innovative Cell Platform bit.bio's advanced opti-ox precision cell programming platform offers opportunities to collaborate with research institutions and biopharmaceutical companies seeking scalable, consistent human cell products for drug discovery and development, facilitating faster project timelines.

Expanding Product Portfolio The recent launch of ioTracker cells and GFP ioMicroglia demonstrates a commitment to diversifying offerings, presenting sales potential to labs and biotechs requiring specialized, visualizable human cell types for both research and therapeutic applications.

Funding and Growth With a recent $30 million financing round and revenue between $10 million and $25 million, bit.bio is positioned for growth and investment in scaling operations, creating opportunities for strategic partnerships and bundled product solutions.

Research and Collaborations Participation in global events like the World Congress on Alternatives and leading industry conferences shows active engagement with the scientific community, opening doors for collaborative projects and exposure to new markets and customer segments.

Strategic Market Focus Serving research, drug discovery, and emerging cell therapy markets, bit.bio’s platform’s ability to produce highly characterized human cells positions it as a key partner for organizations seeking innovative solutions to accelerate research and develop cell-based therapies.

bit.bio Tech Stack

bit.bio uses 8 technology products and services including Canva, RSS, HubSpot Cookie Policy Banner, and more. Explore bit.bio's tech stack below.

  • Canva
    Audio, Video, Graphics
  • RSS
    Content Management System
  • HubSpot Cookie Policy Banner
    Cookie Compliance
  • Swiper
    Javascript Libraries
  • DocuSign
    Miscellaneous
  • Java
    Programming Languages
  • Hadoop
    Programming Languages
  • Greenhouse
    Recruitment Marketing

Media & News

bit.bio's Email Address Formats

bit.bio uses at least 1 format(s):
bit.bio Email FormatsExamplePercentage
First.Last@bit.bioJohn.Doe@bit.bio
65%
First@bit.bioJohn@bit.bio
27%
Last@bit.bioDoe@bit.bio
4%
FLast@bit.bioJDoe@bit.bio
4%

Frequently Asked Questions

Where is bit.bio's headquarters located?

Minus sign iconPlus sign icon
bit.bio's main headquarters is located at The Dorothy Hodgkin Building Babraham Research Campus Cambridge, Cambridgeshire CB22 3FH GB. The company has employees across 4 continents, including EuropeNorth AmericaAsia.

What is bit.bio's official website and social media links?

Minus sign iconPlus sign icon
bit.bio's official website is bit.bio and has social profiles on LinkedIn.

What is bit.bio's SIC code NAICS code?

Minus sign iconPlus sign icon
bit.bio's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does bit.bio have currently?

Minus sign iconPlus sign icon
As of October 2025, bit.bio has approximately 163 employees across 4 continents, including EuropeNorth AmericaAsia. Key team members include Chief Scientific Officer (svp): E. M.Vice President Operations: O. G.Vice President Cell Programming Research: T. M.. Explore bit.bio's employee directory with LeadIQ.

What industry does bit.bio belong to?

Minus sign iconPlus sign icon
bit.bio operates in the Biotechnology Research industry.

What technology does bit.bio use?

Minus sign iconPlus sign icon
bit.bio's tech stack includes CanvaRSSHubSpot Cookie Policy BannerSwiperDocuSignJavaHadoopGreenhouse.

What is bit.bio's email format?

Minus sign iconPlus sign icon
bit.bio's email format typically follows the pattern of First.Last@bit.bio. Find more bit.bio email formats with LeadIQ.

How much funding has bit.bio raised to date?

Minus sign iconPlus sign icon
As of October 2025, bit.bio has raised $30M in funding. The last funding round occurred on Dec 16, 2024 for $30M.

When was bit.bio founded?

Minus sign iconPlus sign icon
bit.bio was founded in 2016.
bit.bio

bit.bio

Biotechnology ResearchCambridgeshire, United Kingdom51-200 Employees

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. 

We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines.

Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies.

To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision.

Collaboration is at the heart of bit.bio. Join us on our journey. 

For more information on bit.bio’s trademarks, visit www.bit.bio/trademarks

Section iconCompany Overview

Headquarters
The Dorothy Hodgkin Building Babraham Research Campus Cambridge, Cambridgeshire CB22 3FH GB
Website
bit.bio
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
51-200

Section iconFunding & Financials

  • $30M

    bit.bio has raised a total of $30M of funding over 5 rounds. Their latest funding round was raised on Dec 16, 2024 in the amount of $30M.

  • $10M$25M

    bit.bio's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $30M

    bit.bio has raised a total of $30M of funding over 5 rounds. Their latest funding round was raised on Dec 16, 2024 in the amount of $30M.

  • $10M$25M

    bit.bio's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.